Last reviewed · How we verify
Cady, Roger, M.D. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Dextromethorphan and quinidine | Dextromethorphan and quinidine | marketed | ||||
| naratriptan HCl | naratriptan HCl | marketed | Triptan (5-HT1B/1D receptor agonist) | 5-HT1B receptor, 5-HT1D receptor | Neurology |
Therapeutic area mix
- Neurology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Damanhour Teaching Hospital · 1 shared drug class
- Merck Sharp & Dohme LLC · 1 shared drug class
- Organon and Co · 1 shared drug class
- Teva Pharmaceuticals USA · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Cady, Roger, M.D.:
- Cady, Roger, M.D. pipeline updates — RSS
- Cady, Roger, M.D. pipeline updates — Atom
- Cady, Roger, M.D. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cady, Roger, M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cady-roger-m-d. Accessed 2026-06-10.